Related Experiment Video
Updated: Feb 1, 2026

Measuring Influenza Neutralizing Antibody Responses to AH3N2 Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells
Published on: November 22, 2017
Sera from different age cohorts in Belgium show limited cross-neutralization between the mumps vaccine and outbreak
T Vermeire1, C Barbezange2, A Francart2
1Department of Viral Diseases, Sciensano, Brussels, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; Center for Medical Biotechnology, VIB, Ghent, Belgium.
Objectives:
Mumps used to affect children between 2 and 15 years old. The mumps-measles-rubella (MMR) vaccine is available, with vaccine coverage rate of about 85% after two vaccine doses. Recently new mumps outbreaks have emerged in highly vaccinated populations; the causes for these new outbreaks are yet unknown. We tested if a difference in seroneutralizing capacity against the vaccine and wild-type viruses existed and if waning immunity could be detected.
Methods:
In this study, 570 serum samples (age group 2-3 years (n = 96), 8-9 years (n = 95), 13-14 years (n = 94), 18-20 years (n = 96), 24-26 years (n = 92) and 50 + years (n = 97)) in Belgium were tested in the rapid fluorescent foci inhibition test for their neutralizing capacity against the vaccine and wild-type viruses.
Results:
Neutralizing antibodies against the vaccine strain were present in 84% (81/97) of the 2-3-year, 74% (70/95) of the 8-9-year, 81% (76/94) of the 13-14-year, 76% (73/96) of the 18-20-year, 67% (62/92) of the 24-26-year and 77% (75/97) of the 50+-year age group serum samples. For all age groups, only about half of these serum samples were also positive for the wild-type virus. The geometric mean titres for the vaccine and wild-type virus for all younger age groups, except for 24-26 years, were significantly different, demonstrating poor in vitro cross-neutralization.
Conclusions:
A possible contribution of antigenic differences between the genotype A and G mumps virus as well as other immune factors, in addition to lower-than-optimal vaccination coverage and waning immunity, could explain the poor in vitro cross-neutralization and should be further studied.
Insights
Mumps outbreaks occur despite high vaccination rates. This study found that antibodies from the MMR vaccine neutralize the vaccine strain but not wild mumps strains effectively, suggesting immune evasion.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Mumps outbreaks are emerging in highly vaccinated populations, challenging the efficacy of the mumps-measles-rubella (MMR) vaccine.
- The reasons behind these recent outbreaks, despite significant vaccine coverage, remain unclear.
Purpose of the Study:
- To investigate potential differences in neutralizing capacity against vaccine and wild-type mumps viruses.
- To assess the presence of waning immunity in vaccinated individuals.
Main Methods:
- 570 serum samples from various age groups in Belgium were analyzed.
- The rapid fluorescent foci inhibition test was used to measure neutralizing antibodies against both vaccine and wild-type mumps viruses.
Main Results:
- Antibodies against the vaccine strain were prevalent across all age groups.
- However, only about half of these samples showed neutralizing capacity against wild-type mumps virus.
- Significant differences in neutralizing antibody titers between vaccine and wild-type strains were observed, indicating poor cross-neutralization.
Conclusions:
- Antigenic differences between mumps virus genotypes (A and G) may contribute to reduced vaccine effectiveness.
- Factors such as suboptimal vaccination coverage and waning immunity could also play a role in mumps outbreaks.
- Further research is needed to understand the poor in vitro cross-neutralization and its implications.
More Related Videos
12:09Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
09:13Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
Published on: November 1, 2011
Related Concept Videos
Cross-Sectional Research
Vaccinations
Crossing Over
The homologous pairs of sister chromosomes—one from the maternal and one from the paternal genome—then begin to align alongside each other lengthwise, matching corresponding DNA positions in a process...
Limiting Reactant
Steps in Outbreak Investigation
The Number e as a Limit